Literature DB >> 17943165

Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.

S Agrawal1, S Koschmieder, N Bäumer, N G P Reddy, W E Berdel, C Müller-Tidow, H Serve.   

Abstract

Pim2 is a serine/threonine kinase expressed at high levels in several malignancies including acute leukemia. Pim2 protein is induced by oncogenic Fms-like tyrosine kinase-3 (Flt3)-internal tandem duplications (ITD), but not by Flt3 wild-type receptor (Flt3-Wt) in response to Flt3 ligand (FL). Here we show that Pim2 can complement Flt3-Wt signaling and induce transformation similar to Flt3-ITD in myeloid cells. Our data demonstrate that Pim2 is necessary but not sufficient for Flt3-ITD-induced transformation of 32D cells and primary bone marrow cells as assessed by colony assays. Pim2-induced clonogenic growth of FL-treated 32D-Flt3-Wt cells. Proliferation of 32D-Flt3-Wt cells was significantly enhanced in FL-treated Pim2-overexpressing cells. This increase was associated with enhanced S-phase cell cycle progression. Pim2-overexpressing cells were resistant to apoptosis induced by growth factor deprivation or treatment with tyrosine kinase inhibitor (PKC412). The Flt3 point mutant D835Y, which is not able to support colony growth of myeloid cells, also induced clonogenic growth in the presence of Pim2. In conclusion, Pim2 is an important target of Flt3-ITD-induced transformation, and overexpression of Pim2 together with Flt3-Wt or D835Y receptor mimics Flt3-ITD-mediated transformation. Pim2 complements with Flt3-Wt signaling to induce proliferation by enhancing G(1)/S-phase progression of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17943165     DOI: 10.1038/sj.leu.2404988

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Novel tumor-suppressor FOXN3 is downregulated in adult acute myeloid leukemia.

Authors:  Hang He; Jinjing Zhang; Yi Qu; Yue Wang; Yan Zhang; Xiaojing Yan; Yan Li; Rui Zhang
Journal:  Oncol Lett       Date:  2019-05-31       Impact factor: 2.967

2.  Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.

Authors:  Yu-Qian Zhao; Yi-Qiong Yin; Jie Liu; Gui-Hua Wang; Jian Huang; Ling-Juan Zhu; Jin-Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

Review 3.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

4.  A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.

Authors:  Amir T Fathi; Omotayo Arowojolu; Ian Swinnen; Takashi Sato; Trivikram Rajkhowa; Donald Small; Fredrik Marmsater; John E Robinson; Stefan David Gross; Matthew Martinson; Shelley Allen; Nicholas C Kallan; Mark Levis
Journal:  Leuk Res       Date:  2011-07-29       Impact factor: 3.156

5.  Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1 (INCA1) regulates proliferation and is repressed by oncogenic signaling.

Authors:  Nicole Bäumer; Lara Tickenbrock; Petra Tschanter; Lisa Lohmeyer; Sven Diederichs; Sebastian Bäumer; Boris V Skryabin; Feng Zhang; Shuchi Agrawal-Singh; Gabriele Köhler; Wolfgang E Berdel; Hubert Serve; Steffen Koschmieder; Carsten Müller-Tidow
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

6.  Genome-wide identification of new Wnt/beta-catenin target genes in the human genome using CART method.

Authors:  Christian Hödar; Rodrigo Assar; Marcela Colombres; Andrés Aravena; Leonardo Pavez; Mauricio González; Servet Martínez; Nibaldo C Inestrosa; Alejandro Maass
Journal:  BMC Genomics       Date:  2010-06-01       Impact factor: 3.969

7.  Cell cycle control in acute myeloid leukemia.

Authors:  Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

8.  Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.

Authors:  Alex N Bullock; Santina Russo; Ann Amos; Nicholas Pagano; Howard Bregman; Judit E Debreczeni; Wen Hwa Lee; Frank von Delft; Eric Meggers; Stefan Knapp
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

9.  Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.

Authors:  Rebekka Grundler; Laurent Brault; Christelle Gasser; Alex N Bullock; Tobias Dechow; Sabine Woetzel; Vanda Pogacic; Antonello Villa; Sabine Ehret; Georgina Berridge; Anke Spoo; Christine Dierks; Andrea Biondi; Stefan Knapp; Justus Duyster; Juerg Schwaller
Journal:  J Exp Med       Date:  2009-08-17       Impact factor: 14.307

10.  Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing.

Authors:  J H Song; N An; S Chatterjee; E Kistner-Griffin; S Mahajan; S Mehrotra; A S Kraft
Journal:  Oncogene       Date:  2014-09-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.